Navigation Links
ValGenesis, Inc. Announces Integration of ValGenesis Solution with Microsoft SharePoint Server

FREMONT, Calif., Aug. 11 /PRNewswire/ -- ValGenesis, Inc., a leading provider of Validation Lifecycle Management solutions, announces the worldwide availability of Microsoft SharePoint Server integration with the latest version of ValGenesis 2.0 for increased enterprise productivity specifically for regulated Pharmaceuticals, Biotech and Medical Devices companies. This offering will seamlessly provide global access, retrieval and storage of corporate validation data and documents generated by ValGenesis within Microsoft SharePoint Server. Companies will be able to keep all the business-critical and compliance data in one central location leveraging real-time reporting and robust search functionality of Microsoft SharePoint Server. ValGenesis Integration with SharePoint follows a familiar usability-driven scenario resulting in an end-to-end secured, 100% paperless, validation lifecycle management solution provided by these two complementary technologies.

"Many Life Sciences companies have standardized on Microsoft SharePoint Server for document management and want the flexibility to leverage this investment. ValGenesis continues to offer state of the art ValGenesis software and now allows customers to use Microsoft SharePoint Server to provide validation data and documents throughout the enterprise through this integration. ValGenesis offers SharePoint users strengthened return on investment and additional usability, functionality and productivity," said Siva Samy, Ph.D., ValGenesis Chief Product Strategist.

About ValGenesis

ValGenesis offers an innovative software platform that serves as the foundation for compliance-based validation life cycle management in regulated companies. ValGenesis is the first Enterprise application to automate the validation lifecycle of GxP systems and to provide 360-degree visibility to the corporate validation process. ValGenesis is designed to fully conform to FDA 21 CFR Part 11 compliance requirements. Through an industry peer review committee, the Parenteral Drug Association (PDA), awarded ValGenesis the prestigious New Innovative Technology award.

    For more information:

    Mike Beaudro, 510-445-0505,

This release was issued through eReleases(TM). For more information, visit

SOURCE ValGenesis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ValGenesis, Inc. Announces Worldwide Release of Validation Life Cycle Management System - ValGenesis 2.0
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... company uBiome, were featured on AngelList early in their initial angel funding process. ... AngelList syndicate for individuals looking to make early stage investments in the microbiome ...
(Date:11/24/2015)... VANCOUVER , Nov. 24, 2015 /CNW/ - iCo ... ICOTF), today reported financial results for the quarter ... are expressed in Canadian dollars and presented under ... the United States ," said Andrew ... "These advancements regarding iCo-008 are not only value ...
(Date:11/24/2015)... 24, 2015 --> ... report "Oligonucleotide Synthesis Market by Product & Services (Primer, ... Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic ... the market is expected to reach USD 1,918.6 Million ... a CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... -- Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting ... Israel time, at the law offices of ... th Floor, Tel Aviv, Israel . ... Izhak Tamir to the Board of Directors; , election of ... approval of an amendment to certain terms of options granted to our ...
Breaking Biology Technology:
(Date:11/2/2015)... MENLO PARK, Calif. , Nov. 2, 2015 /PRNewswire/ ... to $9 million to provide preclinical development services to ... Under the contract, SRI will provide scientific expertise, modern ... a wide variety of preclinical pharmacology and toxicology studies ... --> --> The PREVENT Cancer Drug ...
(Date:10/29/2015)... 2015  Connected health pioneer, Joseph C. Kvedar ... technology-enabled health and wellness, and the business opportunities that ... The Internet of Healthy Things . Long before ... existed, Dr. Kvedar, vice president, Connected Health, Partners HealthCare, ... moving care from the hospital or doctor,s office into ...
(Date:10/27/2015)... SAN JOSE, Calif. , Oct. 27, 2015 /PRNewswire/ ... human interface solutions, today announced that Google has adopted ... family of touch controller solutions to power its newest ... Nexus 6P by Huawei. --> ... ecosystem partners like Google to provide strategic collaboration in ...
Breaking Biology News(10 mins):